<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778137</url>
  </required_header>
  <id_info>
    <org_study_id>CMAB007-001</org_study_id>
    <nct_id>NCT04778137</nct_id>
  </id_info>
  <brief_title>The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety</brief_title>
  <official_title>The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Mabtech Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou Mabtech Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, randomized, double-blind, parallel group, single-dose study to compare the&#xD;
      pharmacokinetics, pharmacodynamics and safety of two formulations of Omalizumab (CMAB007 and&#xD;
      Xolair) in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">April 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures [AUC0-inf]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Area Under the Concentration-time Curve from Time zero to infinity (AUC0-inf) of CMAB007 and Xolair in healthy subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Cmax]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Maximum serum concentration (Cmax) of CMAB007 and Xolair in healthy subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Tmax]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Time to Cmax (Tmax) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [t1/2]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Terminal half-life (t1/2) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [λz]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Terminal elimination rate constant (λz) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Apparent total body clearance (CL/F)]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Apparent total body clearance (CL/F) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics [IgE levels]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Free IgE and total IgE levels (the sum of free and omalizumab-bound IgE) in the serum samples from subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Treatment-Emergent Adverse Events (TEAEs) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [AUC0-t]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-t) of CMAB007 and Xolair in healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Outcome Measures [Vd/F]</measure>
    <time_frame>up to day 106</time_frame>
    <description>Apparent total distribution (Cd/F) of CMAB007 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>up to day 106</time_frame>
    <description>the Immunogenicity of CMAB007 and Xolair in healthy subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CMAB007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg×2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xolair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Biological: CMAB007 Biological: Xolair</description>
    <arm_group_label>CMAB007</arm_group_label>
    <arm_group_label>Xolair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subject between the ages of 18 and 45 years.&#xD;
&#xD;
          -  Subject with a body weight of ≥50 kg and ≤ 75kg and a BMI between 19.0~26.0 kg/m2&#xD;
             (both inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject has a medical history and/or current presence of disease&#xD;
&#xD;
          -  subject has undergone surgery within three months before signing the informed consent;&#xD;
&#xD;
          -  Alcoholics or regular drinkers within 3 months before the test, i.e. those who drink&#xD;
             more than 14 unites of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits&#xD;
             with 40% alcohol), or whose alcohol breath test is positive;&#xD;
&#xD;
          -  Those who have used soft drugs within 3 months prior to signing the informed consent&#xD;
             or hard drugs within 1 year prior the trial; those who have positive drug abuse test&#xD;
             results;&#xD;
&#xD;
          -  Those who smoke more than 10 cigarettes per day on average in the 6 months before&#xD;
             signing the informed consent; or those who have positive nocotine results;&#xD;
&#xD;
          -  Those who have a history of drug or food allergy, or who have special allergy history&#xD;
             (asthma, urticaria, etc.); those who have allergic rhinitis, or are known to be&#xD;
             allergic to any component of the test drug or latex (contained in the syringe needle&#xD;
             cover);&#xD;
&#xD;
          -  Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8&#xD;
             cups, 1 cup =250 ml) every day;&#xD;
&#xD;
          -  Those who have received any drug treatment (including prescription drugs,&#xD;
             over-the-counter drugs, biological products, Traditional Chinese medicine, etc.) and&#xD;
             health care products within 4 weeks befor signing the informed consent;&#xD;
&#xD;
          -  Those who have a blood donation over 400 ml within 3 months, or 200 ml within 1 month&#xD;
             before signing the informed consent, or plan to donate blood during the trail;&#xD;
&#xD;
          -  Those who accept any biological drugs within 3 months, or anti-IgE biological drugs&#xD;
             within 12 months before signing the informed consent;&#xD;
&#xD;
          -  Those who plan to donate sperm within 6 months after the administration of the test&#xD;
             drug;&#xD;
&#xD;
          -  Participants in other clinical trails within 3 months before signing the informed&#xD;
             consent;&#xD;
&#xD;
          -  Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponerma pallidum&#xD;
             antibody is positive;&#xD;
&#xD;
          -  The results of medical examination (ECG, X-ray, B-ultrasonic, physical and laboratory&#xD;
             examination) are clinical significant abnormalities according to the judgment of the&#xD;
             researcher;&#xD;
&#xD;
          -  Anti-nuclear antibody or fecal parasite test is positive;&#xD;
&#xD;
          -  Those who have undergone surgery within 1 months before signing the informed consent,&#xD;
             or plan to undergo surgery during the trail period;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

